Medical Affairs and Regulatory teams restate the same evidence across dossiers, study reports, HTA submissions and medical information responses. Cohesta turns that evidence into governed components — approved once, reused everywhere, kept in sync.
The evidence is approved once. Then it is pasted, paraphrased and re-verified in every document that needs it.
The same comparison, safety table or claim is rebuilt for each dossier, report and response — by different people, in different words.
When the evidence changes, the edit reaches one document and misses the rest. Contradictions surface in review — or with the regulator.
Without lineage back to a controlled source, every copy is verified again. Review time grows with each new document.
Authoring teams often add large volumes of unnecessary information to regulatory documents, leading to multiple manual reviews, revisions, and the risk of contradiction across related documents.
Regulatory reviewers save time during review by not having to re-read the same content over and over across many documents.
Build state-of-the-art gen AI authoring platforms with reusable components that balance flexibility and precision for high-stakes documents.
Industry benchmarks for AI-assisted, structured regulatory writing — the gains Cohesta is built to deliver.
shorter end-to-end authoring cycle for clinical study reports in early gen-AI pilots.
McKinsey, 2025less first-draft CSR writing time at Merck — from 180 to 80 hours on an AI authoring platform.
Merck & McKinsey, 2025Every dossier, report and response carries the current approved component.
Reviewers approve a change a single time; placements inherit it.
Source evidence → component → every placement, traceable end to end.
Bring one dossier and its source evidence. We’ll show the component, the redline and the update across every document.
